Evaluating amyloid-beta as a surrogate endpoint in trials of anti-amyloid drugs in Alzheimer's disease: a Bayesian meta-analysis

Sa Ren, Janharpreet Singh, Sandro Gsteiger +8

The use of amyloid-beta (A${\hat{I}}^2$) clearance to support regulatory approvals of drugs in Alzheimer's disease (AD) remains controversial. We evaluate A${\hat{I}}^2$ as a potential trial-level s…